Foresight Dx is a company that specializes in developing a highly sensitive liquid biopsy minimal residual disease (MRD) test. Their test is designed to detect the earliest hints of cancer relapse, providing valuable insights for early intervention and treatment.

Foresight Dx

Foresight Diagnostics is a precision medicine company developing a novel liquid biopsy test for the measurement of minimal residual disease (MRD) for aid in patient management that is funded by leading diagnostics VC firms in Silicon Valley. Foresight’s cell-free DNA testing platform was developed in the labs of two prominent professors at Stanford University and is backed by several major peer-reviewed publications. The company has garnered significant partnering interest from multiple pharmaceutical companies in oncology and is poised for rapid growth. Foresight Diagnostics is headquartered in Aurora, Colorado.

COM:FORESIGHT-DX

Foresight Dx